{"id":48601,"date":"2026-03-25T14:55:11","date_gmt":"2026-03-25T13:55:11","guid":{"rendered":"https:\/\/digidem-bayern.de\/?p=48601"},"modified":"2026-03-25T14:57:19","modified_gmt":"2026-03-25T13:57:19","slug":"digidem-bayern-statement-zu-lecanemab","status":"publish","type":"post","link":"https:\/\/digidem-bayern.de\/en\/digidem-bayern-statement-zu-lecanemab\/","title":{"rendered":"digiDEM Bayern-Statement zu Lecanemab"},"content":{"rendered":"<p>Die Entscheidung des Gemeinsamen Bundesausschusses (G-BA) vom 19.02.2026, den Zusatznutzen von Lecanemab als \u201anicht belegt\u2018 einzustufen, best\u00e4tigt die Skepsis der Projektleitung von digiDEM hinsichtlich der klinischen Relevanz dieser Therapie. Zwar zeigt die einzige bisher verf\u00fcgbare Studie zu Lecanemab einen statistisch signifikanten Unterschied zwischen dem Medikament und einem Placebo zum Studienende. Die klinische Wirksamkeit ist allerdings als nicht bedeutsam einzustufen und f\u00fcr die Betroffenen im Alltag nicht sp\u00fcrbar. Vor dem Hintergrund der j\u00e4hrlichen Gesamt-Behandlungskosten von rund 38.000 Euro \u2013 was das Hundert- bis Hundertf\u00fcnfzigfache der aktuellen Standardtherapie bspw. mit Donepezil darstellt \u2013 bleibt die Frage der Verh\u00e4ltnism\u00e4\u00dfigkeit im Sinne der Solidargemeinschaft der gesetzlich Krankenversicherten zentral. Ziel der anstehenden Verhandlungen mit dem GKV-Spitzenverband muss es sein, eine angemessene Preisgestaltung durchzusetzen, die sich strikt an der nachgewiesenen Evidenz orientiert und Innovation nicht mit einem pauschalen Freibrief f\u00fcr hohe Forderungen gleichsetzt.<\/p>\n\n\n\n<p>Ohne einen klar quantifizierbaren Mehrwert f\u00fcr die Betroffenen darf eine neue Intervention die begrenzten Ressourcen des Gesundheitssystems nicht unverh\u00e4ltnism\u00e4\u00dfig belasten.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Die Entscheidung des Gemeinsamen Bundesausschusses (G-BA) vom 19.02.2026, den Zusatznutzen von Lecanemab als \u201anicht belegt\u2018 einzustufen, best\u00e4tigt die Skepsis der Projektleitung von digiDEM hinsichtlich der klinischen Relevanz dieser Therapie. Zwar zeigt die einzige bisher verf\u00fcgbare Studie zu Lecanemab einen statistisch signifikanten Unterschied zwischen dem Medikament und einem Placebo zum Studienende. &hellip;<\/p>","protected":false},"author":16,"featured_media":48605,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"qubely_global_settings":"","qubely_interactions":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[8,5],"tags":[12,1216,14,1208,392,449],"class_list":["post-48601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aktuelles-zu-digidem","category-wissenschaft-forschung","tag-demenz-2","tag-demenz-medikamente","tag-digidem","tag-lecanemab","tag-medikamente","tag-wohlbefinden"],"qubely_featured_image_url":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",1600,1067,false],"landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1200x750.jpg",1200,750,true],"portraits":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-540x320.jpg",540,320,true],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1536x1025.jpg",1536,1025,true],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-2048x1366.jpg",2048,1366,true],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-525x350.jpg",525,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1024x1024.jpg",1024,1024,true]},"qubely_author":{"display_name":"Lucas Westermann","author_link":"https:\/\/digidem-bayern.de\/en\/author\/lucas-westermann\/"},"qubely_comment":3,"qubely_category":"<a href=\"https:\/\/digidem-bayern.de\/en\/category\/aktuelles-zu-digidem\/\" rel=\"category tag\">Aktuelles zu digiDEM<\/a> <a href=\"https:\/\/digidem-bayern.de\/en\/category\/wissenschaft-forschung\/\" rel=\"category tag\">Wissenschaft &amp; Forschung<\/a>","qubely_excerpt":"Die Entscheidung des Gemeinsamen Bundesausschusses (G-BA) vom 19.02.2026, den Zusatznutzen von Lecanemab als \u201anicht belegt\u2018 einzustufen, best\u00e4tigt die Skepsis der Projektleitung von digiDEM hinsichtlich der klinischen Relevanz dieser Therapie. Zwar zeigt die einzige bisher verf\u00fcgbare Studie zu Lecanemab einen statistisch signifikanten Unterschied zwischen dem Medikament und einem Placebo zum Studienende. &hellip;","featured_image_urls_v2":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",1600,1067,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1536x1025.jpg",1536,1025,true],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-2048x1366.jpg",2048,1366,true],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-525x350.jpg",525,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1024x1024.jpg",1024,1024,true]},"post_excerpt_stackable_v2":"<p>Die Entscheidung des Gemeinsamen Bundesausschusses (G-BA) vom 19.02.2026, den Zusatznutzen von Lecanemab als \u201anicht belegt\u2018 einzustufen, best\u00e4tigt die Skepsis der Projektleitung von digiDEM hinsichtlich der klinischen Relevanz dieser Therapie. Zwar zeigt die einzige bisher verf\u00fcgbare Studie zu Lecanemab einen statistisch signifikanten Unterschied zwischen dem Medikament und einem Placebo zum Studienende. Die klinische Wirksamkeit ist allerdings als nicht bedeutsam einzustufen und f\u00fcr die Betroffenen im Alltag nicht sp\u00fcrbar. Vor dem Hintergrund der j\u00e4hrlichen Gesamt-Behandlungskosten von rund 38.000 Euro \u2013 was das Hundert- bis Hundertf\u00fcnfzigfache der aktuellen Standardtherapie bspw. mit Donepezil darstellt \u2013 bleibt die Frage der Verh\u00e4ltnism\u00e4\u00dfigkeit im Sinne der Solidargemeinschaft&hellip;<\/p>\n","category_list_v2":"<a href=\"https:\/\/digidem-bayern.de\/en\/category\/aktuelles-zu-digidem\/\" rel=\"category tag\">Aktuelles zu digiDEM<\/a>, <a href=\"https:\/\/digidem-bayern.de\/en\/category\/wissenschaft-forschung\/\" rel=\"category tag\">Wissenschaft &amp; Forschung<\/a>","author_info_v2":{"name":"Lucas Westermann","url":"https:\/\/digidem-bayern.de\/en\/author\/lucas-westermann\/"},"comments_num_v2":"0 comments","yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern<\/title>\n<meta name=\"description\" content=\"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks &quot;Demenzfreundliche Apotheken&quot;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/digidem-bayern.de\/en\/digidem-bayern-statement-zu-lecanemab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern\" \/>\n<meta property=\"og:description\" content=\"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks &quot;Demenzfreundliche Apotheken&quot;.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/digidem-bayern.de\/en\/digidem-bayern-statement-zu-lecanemab\/\" \/>\n<meta property=\"og:site_name\" content=\"digiDEM Bayern\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/digiDEMBayern\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T13:55:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T13:57:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1030x687.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1030\" \/>\n\t<meta property=\"og:image:height\" content=\"687\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lucas Westermann\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lucas Westermann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/\"},\"author\":{\"name\":\"Lucas Westermann\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/c691603c95df780c21130f579673c1a1\"},\"headline\":\"digiDEM Bayern-Statement zu Lecanemab\",\"datePublished\":\"2026-03-25T13:55:11+00:00\",\"dateModified\":\"2026-03-25T13:57:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/\"},\"wordCount\":169,\"commentCount\":0,\"publisher\":{\"@id\":\"\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Medikament_Infusion_Fluessig.jpg\",\"keywords\":[\"Demenz\",\"Demenz-Medikamente\",\"digidem\",\"Lecanemab\",\"Medikamente\",\"Wohlbefinden\"],\"articleSection\":[\"Aktuelles zu digiDEM\",\"Wissenschaft &amp; Forschung\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/\",\"name\":\"digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern\",\"isPartOf\":{\"@id\":\"\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Medikament_Infusion_Fluessig.jpg\",\"datePublished\":\"2026-03-25T13:55:11+00:00\",\"dateModified\":\"2026-03-25T13:57:19+00:00\",\"description\":\"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks \\\"Demenzfreundliche Apotheken\\\".\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Medikament_Infusion_Fluessig.jpg\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Medikament_Infusion_Fluessig.jpg\",\"width\":1600,\"height\":1067},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/digidem-bayern-statement-zu-lecanemab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/digidem-bayern.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"digiDEM Bayern-Statement zu Lecanemab\"}]},{\"@type\":\"WebSite\",\"@id\":\"\\\/#website\",\"url\":\"\\\/\",\"name\":\"digiDEM Bayern\",\"description\":\"Das digitale Demenzregister Bayern erforscht und verbessert die Angebotsstuktur f\u00fcr Menschen mit Demenz und deren Angeh\u00f6rige\",\"publisher\":{\"@id\":\"\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\\\/#organization\",\"name\":\"digiDEM Bayern\",\"url\":\"\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"width\":612,\"height\":357,\"caption\":\"digiDEM Bayern\"},\"image\":{\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/digiDEMBayern\\\/\",\"https:\\\/\\\/x.com\\\/digidem_bayern\",\"https:\\\/\\\/www.instagram.com\\\/digidem.bayern\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/digidem-bayern\\\/\"]},{\"@type\":\"Person\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/c691603c95df780c21130f579673c1a1\",\"name\":\"Lucas Westermann\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/en\\\/author\\\/lucas-westermann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern","description":"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks \"Demenzfreundliche Apotheken\".","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/digidem-bayern.de\/en\/digidem-bayern-statement-zu-lecanemab\/","og_locale":"en_US","og_type":"article","og_title":"digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern","og_description":"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks \"Demenzfreundliche Apotheken\".","og_url":"https:\/\/digidem-bayern.de\/en\/digidem-bayern-statement-zu-lecanemab\/","og_site_name":"digiDEM Bayern","article_publisher":"https:\/\/www.facebook.com\/digiDEMBayern\/","article_published_time":"2026-03-25T13:55:11+00:00","article_modified_time":"2026-03-25T13:57:19+00:00","og_image":[{"width":1030,"height":687,"url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1030x687.jpg","type":"image\/jpeg"}],"author":"Lucas Westermann","twitter_misc":{"Written by":"Lucas Westermann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#article","isPartOf":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/"},"author":{"name":"Lucas Westermann","@id":"\/#\/schema\/person\/c691603c95df780c21130f579673c1a1"},"headline":"digiDEM Bayern-Statement zu Lecanemab","datePublished":"2026-03-25T13:55:11+00:00","dateModified":"2026-03-25T13:57:19+00:00","mainEntityOfPage":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/"},"wordCount":169,"commentCount":0,"publisher":{"@id":"\/#organization"},"image":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg","keywords":["Demenz","Demenz-Medikamente","digidem","Lecanemab","Medikamente","Wohlbefinden"],"articleSection":["Aktuelles zu digiDEM","Wissenschaft &amp; Forschung"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/","url":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/","name":"digiDEM Bayern-Statement zu Lecanemab - digiDEM Bayern","isPartOf":{"@id":"\/#website"},"primaryImageOfPage":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#primaryimage"},"image":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg","datePublished":"2026-03-25T13:55:11+00:00","dateModified":"2026-03-25T13:57:19+00:00","description":"Der Bayerische Landesapothekerkammer unterst\u00fctzt digiDEM Bayern mit Hilfe des Netzwerks \"Demenzfreundliche Apotheken\".","breadcrumb":{"@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#primaryimage","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg","width":1600,"height":1067},{"@type":"BreadcrumbList","@id":"https:\/\/digidem-bayern.de\/digidem-bayern-statement-zu-lecanemab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/digidem-bayern.de\/"},{"@type":"ListItem","position":2,"name":"digiDEM Bayern-Statement zu Lecanemab"}]},{"@type":"WebSite","@id":"\/#website","url":"\/","name":"digiDEM Bavaria","description":"The digital dementia register in Bavaria researches and improves the structure of services for people with dementia and their relatives","publisher":{"@id":"\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/#organization","name":"digiDEM Bavaria","url":"\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/#\/schema\/logo\/image\/","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","width":612,"height":357,"caption":"digiDEM Bayern"},"image":{"@id":"\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/digiDEMBayern\/","https:\/\/x.com\/digidem_bayern","https:\/\/www.instagram.com\/digidem.bayern","https:\/\/www.linkedin.com\/company\/digidem-bayern\/"]},{"@type":"Person","@id":"\/#\/schema\/person\/c691603c95df780c21130f579673c1a1","name":"Lucas Westermann","url":"https:\/\/digidem-bayern.de\/en\/author\/lucas-westermann\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",1600,1067,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1536x1025.jpg",1536,1025,true],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-2048x1366.jpg",2048,1366,true],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-525x350.jpg",525,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2026\/03\/Medikament_Infusion_Fluessig-1024x1024.jpg",1024,1024,true]},"uagb_author_info":{"display_name":"Lucas Westermann","author_link":"https:\/\/digidem-bayern.de\/en\/author\/lucas-westermann\/"},"uagb_comment_info":3,"uagb_excerpt":"Die Entscheidung des Gemeinsamen Bundesausschusses (G-BA) vom 19.02.2026, den Zusatznutzen von Lecanemab als \u201anicht belegt\u2018 einzustufen, best\u00e4tigt die Skepsis der Projektleitung von digiDEM hinsichtlich der klinischen Relevanz dieser Therapie. Zwar zeigt die einzige bisher verf\u00fcgbare Studie zu Lecanemab einen statistisch signifikanten Unterschied zwischen dem Medikament und einem Placebo zum Studienende. &hellip;","_links":{"self":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/48601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/comments?post=48601"}],"version-history":[{"count":2,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/48601\/revisions"}],"predecessor-version":[{"id":48604,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/48601\/revisions\/48604"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media\/48605"}],"wp:attachment":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media?parent=48601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/categories?post=48601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/tags?post=48601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}